Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of BAY 94-9027 in Children Aged 7 to <12 Years With Severe Hemophilia A
NCT05147662Phase 3Completed
- Sponsor
- Bayer
- Start
- Mar 2022
- Primary completion
- Jan 2024
- Modality
- Polymer-based Nanoparticles, Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
A Phase 3 trial of damoctocog alfa pegol in hemophilia A, sponsored by Bayer. Started Mar 2022; status: completed.
02
Drugs
damoctocog alfa pegol
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT05147662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05147662.